TALZENNA® (talazoparib)| Efficacy and safety | TALZENNA efficacy | Secondary endpoints ORR

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

About

TALZENNA MoA

Talzenna MoA

gBRCA testing

Identifying patients

Guidelines

Study design

Baseline characteristics

Efficacy & Safety

TALZENNA efficacy

Primary endpoint & subgroup analysis

Secondary endpoints: ORR

Secondary endpoint: OS

Exploratory endpoints: DoR & TTR

TALZENNA safety

Safety and tolerabillity

Adverse events

Patient-reported outcomes with TALZENNA

Patient-reported outcomes

GHS/QoL

Breast symptoms

Dosing

Dose recommendation and special populations

Dose modifications/management

Patient Profiles

Prescribing Information

Support & Resources

Materials

Elevate

Personalising Breast Cancer Treatment

Understanding and Optimising PARP Inhibitors for mBC

PARP Inhibitors in mBC: the role of Real World Evidence

More than doubled ORR vs chemotherapy^1*†‡

Adapted from TALZENNA^® SmPC, and Litton et al. N Engl J Med. 2018.²

ORR according to line of therapy3^†‡||

Adapted from Ettl et al. ASCO 2019.³

39% of patients in the EMBRACA study received TALZENNA with no prior chemotherapy¹

ORR in gBRCA-mutated LA/mBC patients with TNBC or HR+/HER2- disease^4,5†‡||

Adapted from Eiermann et al. ASCO 2018,⁴ and Rugo et al. JNCI Cancer Spectr. 2020.⁵

Cl=confidence interval; DoR=duration of response; gBRCA=germline breast cancer susceptibility gene; GHS=global health status; HER2-=human epidermal growth factor receptor 2 negative; HR+=hormone receptor-positive; LA/mBC=locally advanced/metastatic breast cancer; OR=odds ratio; ORR=objective response rate; OS=overall survival; QoL=quality of life; RECIST=Response Evaluation Criteria in Solid Tumors; TNBC=triple-negative breast cancer; TTR=time to response.

Capecitabine, eribulin, gemcitabine, or vinorelbine.

Conducted in the intent-to-treat population with measurable disease at baseline. Per RECIST v1.1, confirmation of response was not required.

ORR is the proportion of patients who have a partial or complete response to treatment.

Unconfirmed ORR includes patients with confirmed and unconfirmed responses.

Depicts subgroup analyses from the overall EMBRACA study population. Small patient numbers can be a limitation of subgroup analyses.

These findings should be interpreted with some caution due to the lower numbers of patients in the heavily pretreated (≥2 prior lines of chemotherapy) group.

Explore more

Overall survival

References:

TALZENNA^® Summary of Product Characteristics.

Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379(8):753-763.

Ettl J, Hurvitz SA, Rugo HS, et al. Outcomes of talazoparib vs physician's choice of chemotherapy in patients with advanced breast cancer and a germline BRCA mutation by line of chemotherapy in the EMBRACA trial. Poster presented at: Annual Meeting of the American Society of Clinical Oncology; May 31-June 4, 2019; Chicago, IL. Poster 1071.

Eiermann W, Rugo HS, Diab S, et al. Analysis of germline BRCA1/2 mutated (gBRCAm) hormone receptor–positive (HR+) and triple-negative breast cancer (TNBC) treated with talazoparib (TALA). Poster presented at: Annual Meeting of the American Society of Clinical Oncology; June 1-5, 2018; Chicago, IL. Poster 1070.

Rugo HS, Ettl J, Hurvitz SA, et al. Outcomes in clinically relevant patient subgroups from the EMBRACA study: talazoparib vs physician's choice standard-of-care chemotherapy. JNCI Cancer Spectr. 2020;4(1):1-12.

Litton JK, Hurvitz SA, Mina LA, et al. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: ﬁnal overall survival results from the EMBRACA trial. Ann Oncol. 2020;31(11):1526-1535.

Legal Category: S1A
Further information is available upon request

PP-TAL-IRL-0108 May 2024

TALZENNA efficacy

Improved patient-reported outcomes

Significant improvements in GHS/QoL and breast symptoms⁶

See the results

Appropriate patients for TALZENNA

Meets the needs of patients with gBRCA-mutated HR+/HER2- or triple-negative LA/mBC¹

ccc

View patient profiles

TALZENNA Summary of Product Characteristics

Product Characteristics

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0832. October 2024

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0832. October 2024